HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)By KayeFebruary 17, 20220 Disease burden and current treatment landscape Atopic dermatitis (AD) or atopic eczema is a common inflammatory skin condition that affects…
Current Oral Drugs Available for COVID-19 TreatmentBy Kopal SinghalFebruary 8, 20220 Although majority of COVID-19 cases present as mild to moderate disease which can be managed at home simply with over-the-counter…
